The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema
Open accessAbstract
The current classification system presents challenges to the diagnosis and treatment of patients with diabetes mellitus (DM), in part due to its conflicting and confounding definitions of type 1 DM, type 2 DM, and latent autoimmune diabetes of adults (LADA). The current schema also lacks a foundation that readily incorporates advances in our understanding of the disease and its treatment. For appropriate and coherent therapy, we propose an alternate classification system. The β-cell–centric classification of DM is a new approach that obviates the inherent and unintended confusions of the current system. The β-cell–centric model presupposes that all DM originates from a final common denominator—the abnormal pancreatic β-cell. It recognizes that interactions between genetically predisposed β-cells with a number of factors, including insulin resistance (IR), susceptibility to environmental influences, and immune dysregulation/inflammation, lead to the range of hyperglycemic phenotypes within the spectrum of DM. Individually or in concert, and often self-perpetuating, these factors contribute to β-cell stress, dysfunction, or loss through at least 11 distinct pathways. Available, yet underutilized, treatments provide rational choices for personalized therapies that target the individual mediating pathways of hyperglycemia at work in any given patient, without the risk of drug-related hypoglycemia or weight gain or imposing further burden on the β-cells. This article issues an urgent call for the review of the current DM classification system toward the consensus on a new, more useful system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2003) · Diabetes · doi:10.2337/diabetes.52.1.1 · Cited by 1,482
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 694
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Oslowski, C. M., Hara, T., O'Sullivan-Murphy, B., Kanekura, K., Lu, S., Hara, M., Ishigaki, S., Zhu, L. J., Hayashi, E., Hui, S. T., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.07.005 · Cited by 675
The many faces of diabetes: a disease with increasing heterogeneity
Tuomi, T., Santoro, N., Caprio, S., Cai, M., Weng, J., & Groop, L. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62219-9 · Cited by 652
Insulin Action in Brain Regulates Systemic Metabolism and Brain Function
Kleinridders, A., Ferris, H. A., Cai, W., & Kahn, C. R. (2014) · Diabetes · doi:10.2337/db14-0568 · Cited by 625
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
DeFronzo, R. A., Davidson, J. A., & Del Prato, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01511.x · Cited by 493
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · Diabetes Care · doi:10.2337/dc14-0396 · Cited by 460
Mu, J., Woods, J., Zhou, Y.-P., Roy, R. S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A. D., et al. (2006) · Diabetes · doi:10.2337/db05-1602 · Cited by 449
Sulfonylurea Induced β-Cell Apoptosis in Cultured Human Islets
Maedler, K., Carr, R. D., Bosco, D., Zuellig, R. A., Berney, T., & Donath, M. Y. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0699 · Cited by 333
Garber, A. J., King, A. B., Prato, S. D., Sreenan, S., Balci, M. K., Muñoz-Torres, M., Rosenstock, J., Endahl, L. A., Francisco, A. M. O., & Hollander, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60205-0 · Cited by 325
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
Evans, J. M. M., Ogston, S. A., Emslie-Smith, A., & Morris, A. D. (2006) · Diabetologia · doi:10.1007/s00125-006-0176-9 · Cited by 293
Wilding, J. P. H., Woo, V., Rohwedder, K., Sugg, J., Parikh, S., & for the Dapagliflozin 006 Study Group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12187 · Cited by 291
Exenatide Exerts a Potent Antiinflammatory Effect
Chaudhuri, A., Ghanim, H., Vora, M., Sia, C. L., Korzeniewski, K., Dhindsa, S., Makdissi, A., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1508 · Cited by 284
Rossetti, L., Hawkins, M., Chen, W., Gindi, J., & Barzilai, N. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118013 · Cited by 264
The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity
Tai, N., Wong, F. S., & Wen, L. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9309-0 · Cited by 252
Sitagliptin Exerts an Antinflammatory Action
Makdissi, A., Ghanim, H., Vora, M., Green, K., Abuaysheh, S., Chaudhuri, A., Dhindsa, S., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1544 · Cited by 241
Henry, R. R., Rosenstock, J., Edelman, S., Mudaliar, S., Chalamandaris, A.-G., Kasichayanula, S., Bogle, A., Iqbal, N., List, J., & Griffen, S. C. (2015) · Diabetes Care · doi:10.2337/dc13-2955 · Cited by 238
Obesity, insulin resistance, and type 1 diabetes mellitus
Polsky, S., & Ellis, S. L. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000170 · Cited by 235
Rosenstock, J., Sankoh, S., & List, J. F. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00876.x · Cited by 234
MECHANISMS IN ENDOCRINOLOGY: Gut microbiota in patients with type 2 diabetes mellitus
Allin, K. H., Nielsen, T., & Pedersen, O. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0874 · Cited by 233
Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease
Yarchoan, M., & Arnold, S. E. (2014) · Diabetes · doi:10.2337/db14-0287 · Cited by 231
Perkins, B. A., Cherney, D. Z. I., Partridge, H., Soleymanlou, N., Tschirhart, H., Zinman, B., Fagan, N. M., Kaspers, S., Woerle, H.-J., Broedl, U. C., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2338 · Cited by 231
AACE/ACE comprehensive diabetes management algorithm 2015
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., Davidson, M. B., Einhorn, D., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep15693.cs · Cited by 225
Abdul‐Ghani, M. A., Puckett, C., Triplitt, C., Maggs, D., Adams, J., Cersosimo, E., & DeFronzo, R. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12417 · Cited by 208
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
Nonaka, K., Kakikawa, T., Sato, A., Okuyama, K., Fujimoto, G., Kato, N., Suzuki, H., Hirayama, Y., Ahmed, T., Davies, M. J., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.08.021 · Cited by 208
Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment
Leslie, R. D., Palmer, J., Schloot, N. C., & Lernmark, A. (2016) · Diabetologia · doi:10.1007/s00125-015-3789-z · Cited by 204
Maturity-onset diabetes of the young (MODY): an update
Anık, A., Çatlı, G., Abacı, A., & Böber, E. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0384 · Cited by 198
Del Prato, S. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02847.x · Cited by 197
Reimer, M., Holst, J., & Ahren, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460717 · Cited by 195
Update on Diabetes Classification
Thomas, C. C., & Philipson, L. H. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.015 · Cited by 180
The Suprachiasmatic Nucleus Controls Circadian Energy Metabolism and Hepatic Insulin Sensitivity
Coomans, C. P., van den Berg, S. A. A., Lucassen, E. A., Houben, T., Pronk, A. C. M., van der Spek, R. D., Kalsbeek, A., Biermasz, N. R., Willems van Dijk, K., Romijn, J. A., et al. (2013) · Diabetes · doi:10.2337/db12-0507 · Cited by 173
Metabolic syndrome: a sympathetic disease?
Schlaich, M., Straznicky, N., Lambert, E., & Lambert, G. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70033-6 · Cited by 171
Arnolds, S., Dellweg, S., Clair, J., Dain, M.-P., Nauck, M. A., Rave, K., & Kapitza, C. (2010) · Diabetes Care · doi:10.2337/dc09-2191 · Cited by 167
Influence of Gut Microbiota on Subclinical Inflammation and Insulin Resistance
Carvalho, B. M., & Abdalla Saad, M. J. (2013) · Mediators of Inflammation · doi:10.1155/2013/986734 · Cited by 163
Shimoda, M., Kanda, Y., Hamamoto, S., Tawaramoto, K., Hashiramoto, M., Matsuki, M., & Kaku, K. (2011) · Diabetologia · doi:10.1007/s00125-011-2069-9 · Cited by 161
Zhao, Y., Yang, L., Xiang, Y., Liu, L., Huang, G., Long, Z., Li, X., Leslie, R. D., Wang, X., & Zhou, Z. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3633 · Cited by 142
Diabetes: Have We Got It All Wrong?
Corkey, B. E. (2012) · Diabetes Care · doi:10.2337/dc12-0825 · Cited by 140
Self-citationImmune modulation in humans: implications for type 1 diabetes mellitus
Roep, B. O., & Tree, T. I. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.2 · Cited by 139
Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis
Zhou, K., Donnelly, L. A., Yang, J., Li, M., Deshmukh, H., Zuydam, N. V., Ahlqvist, E., Spencer, C. C. A., Groop, L., Morris, A. D., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70050-6 · Cited by 128
Karlstad, Ø., Starup‐Linde, J., Vestergaard, P., Hjellvik, V., Bazelier, M. T., Schmidt, M. K., Andersen, M., Auvinen, A. P., Haukka, J. K., Furu, K., et al. (2013) · Current Drug Safety · doi:10.2174/15680266113136660067 · Cited by 122
Endocrine disruptors: New players in the pathophysiology of type 2 diabetes?
Chevalier, N., & Fénichel, P. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.09.005 · Cited by 120
Riddle, M., Frias, J., Zhang, B., Maier, H., Brown, C., Lutz, K., & Kolterman, O. (2007) · Diabetes Care · doi:10.2337/dc07-0589 · Cited by 116
Kunutsor, S. K., Apekey, T. A., & Laukkanen, J. A. (2015) · European Journal of Epidemiology · doi:10.1007/s10654-015-0058-x · Cited by 107
Wherrett, D. K., Chiang, J. L., Delamater, A. M., DiMeglio, L. A., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lovell, D. J., Orchard, T. J., Ryan, C. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1429 · Cited by 105
Association between serious ischemic cardiac outcomes and medications used to treat diabetes
Margolis, D. J., Hoffstad, O., & Strom, B. L. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1630 · Cited by 104
Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein.
Chen, J.-Q., Couto, F. M., Minn, A. H., & Shalev, A. (2006) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2006.06.027 · Cited by 103
Straub, R. H. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4688 · Cited by 102
Pietropaolo, M., Barinas‐Mitchell, E., & Kuller, L. H. (2007) · Diabetes · doi:10.2337/db06-0880 · Cited by 96
Simmons, A. L., Schlezinger, J. J., & Corkey, B. E. (2014) · Current Obesity Reports · doi:10.1007/s13679-014-0094-y · Cited by 81
Self-citationLatent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes!
Rolandsson, O., & Palmer, J. P. (2010) · Diabetologia · doi:10.1007/s00125-010-1713-0 · Cited by 72
Progressive Decline in Insulin Levels in Rabson-Mendenhall Syndrome
Longo, N., Wang, Y., & Pasquali, M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.8.5902 · Cited by 71
Epigenetic dynamics in immunity and autoimmunity
Zhao, M., Wang, Z., Yung, S., & Lu, Q. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.05.022 · Cited by 69
Grant, S. F. A., Hakonarson, H. H., & Schwartz, S. S. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0029 · Cited by 66
Self-citationHyperinsulinemic syndrome: The metabolic syndrome is broader than you think
Kelly, C. T., Mansoor, J., Dohm, G. L., Chapman, W. H. H., Pender, J. R., & Pories, W. J. (2014) · Surgery · doi:10.1016/j.surg.2014.04.028 · Cited by 64
Mechanism of the mitogenic influence of hyperinsulinemia
Draznin, B. (2011) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-3-10 · Cited by 63
Understanding type 2 diabetes: from genetics to epigenetics
Raciti, G. A., Longo, M., Parrillo, L., Ciccarelli, M., Mirra, P., Ungaro, P., Formisano, P., Miele, C., & Bèguinot, F. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0741-0 · Cited by 59
Sustained Enhancement of Ca2+ Influx by Glibenclamide Induces Apoptosis in RINm5F Cells
Iwakura, T., Fujimoto, S., Kagimoto, S., Inada, A., Kubota, A., Someya, Y., Ihara, Y., Yamada, Y., & Seino, Y. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2616 · Cited by 58
Adjunct therapy for type 1 diabetes mellitus
Lebovitz, H. E. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.49 · Cited by 57
Renukuntla, V. S., Ramchandani, N., Ilkowitz, J. T., Cantwell, M., & Heptulla, R. A. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814542153 · Cited by 57
Ghazi, T., Rink, L., Sherr, J. L., & Herold, K. C. (2013) · Diabetes Care · doi:10.2337/dc13-1169 · Cited by 55
The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern
Currie, C. J., & Johnson, J. A. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01469.x · Cited by 54
Guglielmi, C., Palermo, A., & Pozzilli, P. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2345 · Cited by 53
Erion, K., Berdan, C. A., Burritt, N. E., Corkey, B. E., & Deeney, J. T. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.620351 · Cited by 52
Self-citationLADA: Time for a New Definition
REDONDO, M. J. (2013) · Diabetes · doi:10.2337/db12-1171 · Cited by 51
Progressive Decline in Insulin Levels in Rabson-Mendenhall Syndrome
Longo, N. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2623 · Cited by 50
Basile, K. J., Guy, V. C., Schwartz, S. S., & Grant, S. F. A. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0550-9 · Cited by 49
Self-citationGut microbiota as a key player in triggering obesity, systemic inflammation and insulin resistance.
Escobedo, G., López‐Ortiz, E., & Torres-Castro, I. (2014) · PubMed · Cited by 42
IAPP boosts islet macrophage IL-1 in type 2 diabetes
Mandrup-Poulsen, T. R. (2010) · Nature Immunology · doi:10.1038/ni1010-881 · Cited by 36
Armato, J., DeFronzo, R. A., Abdul-Ghani, M., & Ruby, R. (2012) · Endocrine Practice · doi:10.4158/ep11194.or · Cited by 35
Insulin Resistance: Pathophysiology and Rationale for Treatment
Muntoni, S., & Muntoni, S. (2011) · Annals of Nutrition and Metabolism · doi:10.1159/000323395 · Cited by 34
Biswas, S. K., Mohtarin, S., Mudi, S. R., Anwar, T., Banu, L. A., Alam, S. M. K., Fariduddin, M., & Arslan, M. (2015) · Journal of Diabetes Research · doi:10.1155/2015/150325 · Cited by 26
Subauste, A. R., Gianani, R., Chang, A. M., Plunkett, C. D., Pietropaolo, S. L., Zhang, Y.-J., Barinas‐Mitchell, E., Kuller, L. H., Gałecki, A. T., Halter, J. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106537 · Cited by 22
The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus
Munir, K. M., & Davis, S. N. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1084502 · Cited by 22
Effect of Pioglitazone on the Course of New-Onset Type 1 Diabetes Mellitus
Sue, T. K., Godil, M. A., Harry, L. A., & Allen, W. T. (2013) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.981 · Cited by 22
Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes
Schwartz, S. S., DeFronzo, R. A., & Umpierrez, G. E. (2014) · Postgraduate Medicine · doi:10.1080/00325481.2015.996504 · Cited by 12
Self-citationEvidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
Schwartz, S. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2757 · Cited by 8
Self-citationCan genetics improve precision of therapy in diabetes?
Groop, L., Storm, P., & Rosengren, A. H. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.06.005 · Cited by 6
Lipid Effects and Cardiovascular Disease Risk Associated with Glucose-Lowering Medications
Stähli, B. E., Gebhard, C., & Tardif, J. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0608-6 · Cited by 4
What defines disease in an age of genetics and biomarkers?
Gottlieb, P. A. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000172 · Cited by 2
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360
“Evolving data suggest a role for adipokine dysregulation, inflammation, and abnormalities in gut microbiota, immune dysregulation, and inflammation have emerged as important pathophysiological factors [7].”
Background2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Metadata
- Authors
- Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-01-12
- Volume
- 39
- Issue
- 2
- Pages
- 179-186
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2269288506
- Cited by
- 329
- References
- 88
- FWCI
- 29.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.